March 20, 2020

To
The Manager
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

To
The Manager,
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050

Scrip Code- 532523
Scrip Symbol- Biocon

Dear Sir/Madam,

Subject: Company Statement - Biocon Receives EIR for Small Molecules API Manufacturing Facility for Post-Approval and GMP U.S. FDA Inspection.

Please find below the “Company Statement” on the subject matter.

“This is to inform you that Biocon has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the Post-Approval and GMP inspection of its Small Molecules API Manufacturing Facility at 20th KM, Biocon Campus, Bengaluru, conducted between Feb 20 and Feb 26, 2020. The EIR has been closed with a “VAI” classification for the observations. At the conclusion of the inspection last month the agency had issued a Form 483, with two observations, which were procedural in nature and are being addressed by the Company.

We remain committed to global standards of Quality and Compliance." - Company Spokesperson

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

_____________________
Mayank Verma
Company Secretary and Compliance Officer